Yükleniyor... / Loading...
This study examined the transcription factor Runx2 in necrotic tissue samples from patients with osteonecrosis of the femoral head. It included patients undergoing total hip replacement for the first time due to femoral head osteonecrosis or hip osteoarthritis. It was a non-phase study and has been completed.
The summary above is a plain-language rendering of the official record. The original English title is shown for reference.
Criteria are reproduced from the ClinicalTrials.gov record in the original English. Only the trial team can determine eligibility.
Inclusion Criteria: * Diagnosed as ONFH at Ficat Stage III-IV by anteroposterior and lateral X- ray and/or computed tomography (CT) images * Diagnosed with hip joint osteoarthritis by laboratory examinations and X-ray images * Subjected to total hip replacement for the first time * Able to tolerate anesthesia and surgery * Provide informed consent regarding the benefits and risks of participation in the trial Exclusion Criteria: * Complicated by severe primary cardiovascular disease, hepatic and/or renal inadequacy, or hematopoietic system disorders * Pregnant or lactating woman * With blood coagulation disorder * With a history of epilepsy or mental disorder * Have participated in other clinical trials within 30 days prior to recruitment * Are taking part in other clinical trials * Cannot manage him/herself or have poor self-control ability * Human immunodeficiency virus (HIV)-positive or hepatitis virus-positive * Active systemic or local infection * Poor tolerance to total hip replacement